Clinical Trial

Effect of Mizagliflozin on Hypoglycemia in Patients With Post-Bariatric Hypoglycemia

Study acronym: EMERGE
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
VGX-001-013 (EMERGE) is a Phase 2b study to evaluate an investigational new drug, mizagliflozin, for safety, tolerability and its ability to prevent low blood sugar in patients with post-bariatric hypoglycemia.
Trial Details
NCT Number NCT07760961
Lead Sponsor Vogenx, Inc.
Conditions Postbariatric Hypoglycemia
Enrollment 36 participants
Start Date 2026-10
Primary Completion 2027-10 (estimated)
Study Completion 2028-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-12